Preclinical Evaluation of Artesunate as an Antineoplastic Agent in Ovarian Cancer Treatment
<b> </b>Background: Ovarian cancer is the deadliest gynecologic malignancy despite current first-line treatment with a platinum and taxane doublet. Artesunate has broad antineoplastic properties but has not been investigated in combination with carboplatin and paclitaxel for ovarian canc...
Main Authors: | Anthony McDowell, Kristen S. Hill, J. Robert McCorkle, Justin Gorski, Yilin Zhang, Ameen A. Salahudeen, Fred Ueland, Jill M. Kolesar |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-02-01
|
Series: | Diagnostics |
Subjects: | |
Online Access: | https://www.mdpi.com/2075-4418/11/3/395 |
Similar Items
-
Anticoccidial activity of Artemisinin and Extract of Artemesia annua leaves in chicken infected by Eimeria tenella
by: Ening Wiedosari, et al.
Published: (2018-03-01) -
Population pharmacokinetics and pharmacodynamics of the artesunate–mefloquine fixed dose combination for the treatment of uncomplicated falciparum malaria in African children
by: Monia Guidi, et al.
Published: (2019-04-01) -
Bioequivalence of Two Intravenous Artesunate Products with Its Active Metabolite Following Single and Multiple Injections
by: Qigui Li, et al.
Published: (2011-01-01) -
A Randomised, Double Blind, Placebo-Controlled Pilot Study of Oral Artesunate Therapy for Colorectal Cancer
by: Sanjeev Krishna, et al.
Published: (2015-01-01) -
KEAP1 Is Required for Artesunate Anticancer Activity in Non-Small-Cell Lung Cancer
by: Kristen S. Hill, et al.
Published: (2021-04-01)